The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy

Intraperitoneal Injection of a Hairpin RNA–Expressing Plasmid Targeting Urokinase-Type Plasminogen Activator (uPA) Receptor and uPA Retards Angiogenesis and Inhibits Intracranial Tumor Growth in Nude Mice

Gondi, C. S., Lakka, S. S., Dinh, D. H., Olivero, W. C., Gujrati, M., & Rao, J. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3032 · Cited by 92

Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator

Katz, B. A., Mackman, R. L., Luong, C., Radika, K., Martelli, A., Sprengeler, P. A., Wang, J., Chan, H., & Wong, L. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00104-6 · Cited by 91

Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.

Kirchheimer, J. C., Wojta, J., Christ, G., & Binder, B. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.14.5424 · Cited by 90

Transcriptional and posttranscriptional regulation of the plasminogen activator system

Medcalf, R. L., Muñoz‐Cánoves, P., & Nagamine, Y. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-12-0814 · Cited by 90

The biology of integrins.

Stupack, D. G. (2007) · PubMed · Cited by 89

Metastasis Markers in Bladder Cancer: A Review of the Literature and Clinical Considerations

Gontero, P., Banisadr, S., Frea, B., & Brausi, M. A. (2004) · European Urology · doi:10.1016/j.eururo.2004.04.001 · Cited by 89

The role of vitronectin as multifunctional regulator in the hemostatic and immune systems

Preissner, K. T. (1989) · Annals of Hematology · doi:10.1007/bf00349063 · Cited by 87

β-Catenin Up-Regulates the Expression of the Urokinase Plasminogen Activator in Human Colorectal Tumors

Hiendlmeyer, E., Regus, S., Wassermann, S., Hlubek, F., Haynl, A., Dimmler, A. W., Koch, C., Knoll, C., van Beest, M., Reuning, U., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3627-2 · Cited by 87

Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols

Castonguay, A. (1997) · Carcinogenesis · doi:10.1093/carcin/18.3.491 · Cited by 86

Structure-function relationships in serpins: current concepts and controversies.

Gils, A., & Declerck, P. J. (1998) · PubMed · Cited by 85

Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1

Setyono-Han, B., Stürzebecher, J., Schmalix, W. A., Muehlenweg, B., Sieuwerts, A. M., Timmermans, M. A. M., Magdolen, V., Schmitt, M., Klijn, J. G. M., & Foekens, J. A. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-11-0712 · Cited by 85

Transcription Factor Decoy Molecules Based on a Peptide Nucleic Acid (PNA)-DNA Chimera Mimicking Sp1 Binding Sites

Borgatti, M., Lampronti, I., Romanelli, A., Pedone, C., Saviano, M., Bianchi, N., Mischiati, C., & Gambari, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206780200 · Cited by 85

Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells

Meissauer, A., Kramer, M. D., Hofmann‐Apitius, M., Erkell, L. J., Jacob, E., Schirrmacher, V., & Brunner, G. (1991) · Experimental Cell Research · doi:10.1016/0014-4827(91)90064-2 · Cited by 84

Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.

Xing, R. H., Mazar, A. P., Henkin, J., & Rabbani, S. A. (1997) · PubMed · Cited by 84

Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice

Angelucci, A., Gravina, G. L., Rucci, N., Millimaggi, D., Festuccia, C., Muzi, P., Teti, A. M., Vicentini, C., & Bologna, M. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01100 · Cited by 83

Plasminogen Activator Inhibitor-1 Levels and Polymorphisms

Francis, C. W. (2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-1401-pailap · Cited by 82

Unexpected Role of Plasminogen Activator Inhibitor 1 in Cell Adhesion and Detachment

Czekay, R., & Loskutoff, D. J. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422901102 · Cited by 82

Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis

Nozaki, S., Endo, Y., Kawashiri, S., Nakagawa, K., Yamamoto, E., Yonemura, Y., & Sasaki, T. (1998) · Oral Oncology · doi:10.1016/s1368-8375(97)00028-6 · Cited by 82

Binding of urokinase-type plasminogen activator–plasminogen activator inhibitor-1 complex to the endocytosis receptors α2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor

RODENBURG, W. K., Kjøller, L., Petersen, H. H., & Andreasen, A. (1998) · Biochemical Journal · doi:10.1042/bj3290055 · Cited by 82

The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene

Riccio, A., Lund, L. R., Sartorio, R., Lania, A., Anderasen, P. A., Danø, K., & Blasi, F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.7.2805 · Cited by 81

Requirement of an Upstream AP-1 Motif for the Constitutive and Phorbol Ester-inducible Expression of the Urokinase-type Plasminogen Activator Receptor Gene

Lengyel, E. R., Wang, H., Stepp, E., Juarez, J., Wang, Y., Doe, W. F., Pfarr, C. M., & Boyd, D. D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23176 · Cited by 81

Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells

Chekhun, V. F., Kulik, G. I., Yurchenko, O. V., Tryndyak, V., Todor, I. N., Luniv, L. S., Tregubova, N. A., Pryzimirska, T. V., Montgomery, B. A., Rusetska, N., et al. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.038 · Cited by 81

Multiple instability-regulating sites in the 3' untranslated region of the urokinase-type plasminogen activator mRNA.

Nanbu, R., Menoud, P. A., & Nagamine, Y. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4920 · Cited by 78

Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers

Gavrilov, D. K., Kenzior, O., Evans, M., Calaluce, R., & Folk, W. R. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00077-6 · Cited by 78

Cloned fragment of diphtheria toxin linked to T cell-specific antibody identifies regions of B chain active in cell entry.

Colombatti, M., Greenfield, L., & Youle, R. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35741-1 · Cited by 77

CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review

Béné, M. C., Castoldi, G., Knapp, W., Rigolin, G. M., Escribano, L., Lemež, P., Ludwig, W., Matutes, E., Orfao, A., Lanza, F., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403250 · Cited by 77

MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer

Cuevas, B. D., Winter-Vann, A. M., Johnson, N. L., & Johnson, G. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209507 · Cited by 76

Prognostic significance of proteolytic enzymes in human brain tumors

Bindal, A. K., Hammoud, M. A., Shi, W. M., Wu, S. Z., Sawaya, R. A., & Rao, J. S. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052886 · Cited by 75

Nuclear Factor Kappa B is a Promising Therapeutic Target in Inflammatory Lung Disease

Park, G. Y., & Christman, J. W. (2006) · Current Drug Targets · doi:10.2174/138945006777435317 · Cited by 74

Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow

Heiss, M. M., Simon, E. H., Beyer, B. C. M., Gruetzner, K. U., Tarabichi, A., Babic, R., Schildberg, F. W., & Allgayer, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.003 · Cited by 74

Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer

Seetoo, D., Crowe, P. J., Russell, P. J., & Yang, J. (2003) · Journal of Surgical Oncology · doi:10.1002/jso.10210 · Cited by 73

Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity

Angelucci, A., Gravina, G. L., Biordi, L. A., Millimaggi, D., Muzi, P., Vicentini, C., Bologna, M., & Festuccia, C. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-09-0637 · Cited by 72

Green Tea Polyphenols Modulate Secretion of Urokinase Plasminogen Activator (uPA) and Inhibit Invasive Behavior of Breast Cancer Cells

Slivova, V., Zaloga, G. P., DeMichele, S. J., Mukerji, P., Huang, Y. S., Siddiqui, R. A., Harvey, K. A., Valachovicova, T., & Slíva, D. (2005) · Nutrition and Cancer · doi:10.1207/s15327914nc5201_9 · Cited by 72

Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells

Cohen, R., Xi, X., Crowley, C., Lucas, B., Levinson, A. D., & Shuman, M. (1991) · Blood · doi:10.1182/blood.v78.2.479.479 · Cited by 72

Helicobacter pyloriInduces Plasminogen Activator Inhibitor 2 in Gastric Epithelial Cells through Nuclear Factor-κB and RhoA

Varró, A., Noble, P., Pritchard, D. M., Kennedy, S., Hart, C. A., Dimaline, R., & Dockray, G. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2399 · Cited by 71

Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.

Harvey, S. R., Hurd, T. C., Markus, G., Martinick, M., Penetrante, R. M., Tan, D., Venkataraman, P., DeSouza, N., Sait, S. N. J., Driscoll, D. L., et al. (2003) · PubMed · Cited by 71

Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade

Lengyel, E. R., Wang, H., Gum, R. J., Simon, C., Wang, Y., & Boyd, D. D. (1997) · Oncogene · doi:10.1038/sj.onc.1201098 · Cited by 71

Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2

D'Orazio, D., Besser, D., Marksitzer, R., Kunz, C., Hume, D. A., Kiefer, B., & Nagamine, Y. (1997) · Gene · doi:10.1016/s0378-1119(97)00445-9 · Cited by 70

Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer.

Miyake, H., Hara, I., Yamanaka, K., Arakawa, S., & Kamidono, S. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.3.535 · Cited by 70

Effect of pharmacologic plasminogen activator inhibitor‐1 inhibition on cell motility and tumor angiogenesis

Leik, C. E., Su, E. J., Nambi, P., Crandall, D., & Lawrence, D. A. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02244.x · Cited by 70

Lung carcinoma in African Americans and whites

Schwartz, A. G., & Swanson, G. M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970101)79:1 · Cited by 70

Suppression of Urokinase Expression and Invasiveness by Urinary Trypsin Inhibitor Is Mediated through Inhibition of Protein Kinase C- and MEK/ERK/c-Jun-dependent Signaling Pathways

Kobayashi, H., Suzuki, M., Tanaka, Y., Hirashima, Y., & Terao, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007650200 · Cited by 70

(4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase

Sperl, S., Jacob, U., de Prada, N. A., Stürzebecher, J., Wilhelm, O. G., Bode, W., Magdolen, V., Huber, R., & Moroder, L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5113 · Cited by 70

Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer

Memarzadeh, S., Kozak, K. R., Chang, L., Natarajan, S., Shintaku, P. I., Reddy, S. T., & Farias‐Eisner, R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152127499 · Cited by 70

An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.

Guo, Y., Mazar, A. P., Lebrun, J. J., & Rabbani, S. A. (2002) · PubMed · Cited by 70

Isolation of a High Affinity Inhibitor of Urokinase-type Plasminogen Activator by Phage Display of Ecotin

Wang, C., Yang, Q., & Craik, C. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.20.12250 · Cited by 69

Anthocyanidins inhibit migration of glioblastoma cells: Structure‐activity relationship and involvement of the plasminolytic system

Lamy, S., Lafleur, R., Bédard, V., Moghrabi, A., Barrette, S., Gingras, D., & Béliveau, R. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21023 · Cited by 69

Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin

Liu, S., Redeye, V., Kuremsky, J. G., Kuhnen, M., Molinolo, A., Bugge, T. H., & Leppla, S. H. (2005) · Nature Biotechnology · doi:10.1038/nbt1091 · Cited by 68

Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial

Berkenblit, A., Matulonis, U. A., Kroener, J. F., Dezube, B. J., Lam, G. N., Cuasay, L. C., Brünner, N., Jones, T. R., Silverman, M. H., & Gold, M. A. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.05.023 · Cited by 67

An AU-rich sequence in the 3'-UTR of plasminogen activator inhibitor type 2 (PAI-2) mRNA promotes PAI-2 mRNA decay and provides a binding site for nuclear HuR

Maurer, F. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.7.1664 · Cited by 67

Cytotoxic sensitivity to tumor necrosis factor-? in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin)

Sintich, S. M., Steinberg, J., Kozlowski, J. M., Lee, C., Pruden, S. J., Sayeed, S., & Sensibar, J. A. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990501)39:2 · Cited by 66

Development of Irreversible Diphenyl Phosphonate Inhibitors for Urokinase Plasminogen Activator

Joossens, J., der Veken, P. V., Lambeir, A., Augustyns, K., & Haemers, A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0499209 · Cited by 66

EXPRESSION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR, UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR AND PLASMINOGEN ACTIVATOR INHIBITORS IN PATIENTS WITH RENAL CELL CARCINOMA: CORRELATION WITH TUMOR ASSOCIATED MACROPHAGE AND PROGNOSIS

Ohba, K., Miyata, Y., Kanda, S., Koga, S., Hayashi, T., & Kanetake, H. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000165150.46006.92 · Cited by 66

Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer

Sakakibara, T., Hibi, K., Koike, M., Fujiwara, M., Kodera, Y., Ito, K., & Nakao, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602743 · Cited by 65

Inhibition of the Interaction of Urokinase-Type Plasminogen Activator (uPA) with Its Receptor (uPAR) by Synthetic Peptides

Bürgle, M., Koppitz, M., Riemer, C., Kessler, H., König, B., Weidle, U. H., Kellermann, J., Lottspeich, F., Graeff, H., Schmitt, M., et al. (1997) · Biological Chemistry · doi:10.1515/bchm.1997.378.3-4.231 · Cited by 65

Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder

Shariat, S. F., Monoski, M. A., Andrews, B., Wheeler, T. M., Lerner, S. P., & Slawin, K. M. (2003) · Urology · doi:10.1016/s0090-4295(02)02522-0 · Cited by 65

Identification of Novel Binding Interactions in the Development of Potent, Selective 2-Naphthamidine Inhibitors of Urokinase. Synthesis, Structural Analysis, and SAR of N -Phenyl Amide 6-Substitution

Wendt, M. D., Rockway, T. W., Geyer, A. G., McClellan, W. J., Weitzberg, M., Zhao, X., Mantei, R. A., Nienaber, V. L., Stewart, K. D., Klinghofer, V., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0300072 · Cited by 65

Evaluation of ovarian findings in asymptomatic postmenopausal women with color doppler ultrasound

Vuento, M., PIRHONEN, J. P., Mäkinen, J., Laippala, P. J., Grönroos, M. A., & Salmi, T. (1995) · Cancer · doi:10.1002/1097-0142(19951001)76:7 · Cited by 65

siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells

Subramanian, R., Gondi, C. S., Lakka, S. S., Jutla, A., & Rao, J. S. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.4.831 · Cited by 65

Plasminogen Activator Inhibitor Type 2 Contains mRNA Instability Elements within Exon 4 of the Coding Region

Tierney, M. J., & Medcalf, R. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010627200 · Cited by 63

Protein synthesis inhibition stabilizes urokinase-type plasminogen activator mRNA. Studies in vivo and in cell-free decay reactions.

Altus, M. S., & Nagamine, Y. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54839-0 · Cited by 63

Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease

Duffy, M. J., Duggan, C. R., Mulcahy, H. E., McDermott, E. W. M., & O’Higgins, N. J. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.6.1177 · Cited by 62

Urokinase system expression in gastric carcinoma

Beyer, B. C. M., Heiss, M. M., Simon, E. H., Gruetzner, K. U., Babic, R., Jauch, K., Schildberg, F. W., & Allgayer, H. (2006) · Cancer · doi:10.1002/cncr.21682 · Cited by 62

Prognostic relevance of TGF‐β1 and PAI‐1 in cervical cancer

Hazelbag, S., Kenter, G. G., Gorter, A., & Fleuren, G. J. (2004) · International Journal of Cancer · doi:10.1002/ijc.20512 · Cited by 62

Multimarker phenotype predicts adverse survival in patients with lymph node‐negative colorectal cancer

Zlobec, I., Minoo, P., Baumhoer, D., Baker, K., Terracciano, L., Jass, J. R., & Lugli, A. (2007) · Cancer · doi:10.1002/cncr.23208 · Cited by 61

Clinical significance of urokinase‐type plasminogen activator activity in hepatocellular carcinoma

Itoh, T., Hayashi, Y., Kanamaru, T., Morita, Y., Suzuki, S., Wang, W., Zhou, L., Rui, J., Yamamoto, M., Kuroda, Y., et al. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02150.x · Cited by 61

Inhibition of the invasion capacity of carcinoma cells by WX‐UK1, a novel synthetic inhibitor of the urokinase‐type plasminogen activator system

Ertongur, S., Lang, S., Mack, B., Wosikowski, K., Muehlenweg, B., & Gires, O. (2004) · International Journal of Cancer · doi:10.1002/ijc.20192 · Cited by 61

Expression and Characterization of Pro α2-Plasmin Inhibitor

Sumi, Y., Ichikawa, Y., Nakamura, Y., Miura, O., & Aoki, N. (1989) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a122920 · Cited by 61

A bifunctional hybrid molecule of the amino‐terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis

Kobayashi, H., Sugino, D., She, M. Y., Ohi, H., Hirashima, Y., Shinohara, H., Fujie, M., Shibata, K., & Terao, T. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2530817.x · Cited by 60

Urokinase-Type Plasminogen Activator Expression in Human Prostate Carcinomas

Veldhuizen, P. J. V., Sadasivan, R., Cherian, R., & Wyatt, A. (1996) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)41739-2 · Cited by 60

High‐affinity urokinase‐derived cyclic peptides inhibiting urokinase/urokinase receptor‐interaction: effects on tumor growth and spread

Sato, S., Kopitz, C., Schmalix, W. A., Muehlenweg, B., Kessler, H., Schmitt, M., Krüger, A., & Magdolen, V. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03311-2 · Cited by 60

Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.

Werle, B., Kotzsch, M., Lah, T. T., Kos, J., Gabrijelcic‐Geiger, D., Spieß, E., Schirren, J., Ébert, W., Fiehn, W., Luther, T., et al. (2004) · PubMed · Cited by 60

Selective Urokinase-Type Plasminogen Activator Inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines

Fish, P. V., Barber, C., Brown, D. G., Butt, R. P., Collis, M. G., DICKINSON, R. P., Henry, B. T., Horne, V. A., Huggins, J. P., King, E., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061066t · Cited by 60

Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)

Krüger, A., Soeltl, R., Lutz, V., Wilhelm, O. G., Magdolen, V., Rojo, E. E., Hantzopoulos, P. A., Graeff, H., Gänsbacher, B., & Schmitt, M. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700144 · Cited by 60

Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells.

Henderson, B. R., Tansey, W. P., Phillips, S. M., Ramshaw, I. A., & Kefford, R. F. (1992) · PubMed · Cited by 59

Re-engineering of Human Urokinase Provides a System for Structure-based Drug Design at High Resolution and Reveals a Novel Structural Subsite

Nienaber, V. L., Wang, J., Davidson, D. J., & Henkin, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.7239 · Cited by 58

Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.

Nekarda, H., Schlegel, P. G., Schmitt, M., Stark, M., Mueller, J. D., Fink, U., & Siewert, J. R. (1998) · PubMed · Cited by 58

Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.

Mani, S., Rudin, C. M., Kunkel, K., Holmlund, J., Geary, R. S., Kindler, H. L., Dorr, F. A., & Ratain, M. J. (2002) · PubMed · Cited by 58

Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.

Schmitt, M., Goretzki, L., Jänicke, F., Calvete, J. J., Eulitz, M., Kobayashi, H., Chucholowski, N., & Graeff, H. (1991) · PubMed · Cited by 58

Expression and functional role of urokinase‐type plasminogen activator receptor in normal and acute leukaemic cells

Lanza, Castoldi, Castagnar, Todd, Moretti, Spisani, Latorraca, Focarile, Roberti, & Traniello (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00932.x · Cited by 57

Regulation of Plasminogen Gene Expression by Interleukin-6

Jenkins, G. R., Seiffert, D., Parmer, R. J., & Miles, L. A. (1997) · Blood · doi:10.1182/blood.v89.7.2394 · Cited by 56

Binding site of α2-plasmin inhibitor to plasminogen

Sugiyama, N., Sasaki, T., Iwamoto, M., & Abiko, Y. (1988) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(88)90094-5 · Cited by 55

Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoter

Cousin, E., Medcalf, R. L., Bergonzelli, G. E., & Kruithof, E. K. O. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.14.3881 · Cited by 55

Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma

Dass, C. R., Nadesapillai, A. P. W., Robin, D., Howard, M. L., Fisher, J., Zhou, H., & Choong, P. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-006-9004-3 · Cited by 55

Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.

Skelly, M. M., Troy, A., Duffy, M. J., Mulcahy, H. E., Duggan, C., Connell, T. G., O’Donoghue, D. P., & Sheahan, K. D. (1997) · PubMed · Cited by 55

Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: Relation to prognosis and angiogenesis

Offersen, B. V., Pfeiffer, P., Andreasen, P. A., & Overgaard, J. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.11.018 · Cited by 55

Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice

Kawamura, I., Morishita, R., Tsujimoto, S., Manda, T., Tomoi, M., Tomita, N., Goto, T., Ogihara, T., & Kaneda, Y. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301478 · Cited by 54

Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.

Takeuchi, Y., Nakao, A., Harada, A., Nonami, T., Fukatsu, T., & Takagi, H. (1993) · PubMed · Cited by 53

Evidence for the Regulation of Urokinase and Tissue Type Plasminogen Activators by the Serpin, Protein C Inhibitor, in Semen and Blood Plasma

España, F., Estellés, A., Fernández, P. J., Gilabert, J., Sánchez-Cuenca, J. M., & Griffin, J. H. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649712 · Cited by 53

Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice

Mutoh, M., Niho, N., Komiya, M., Takahashi, M., Ohtsubo, R., Nakatogawa, K., Ueda, K., Sügimura, T., & Wakabayashi, K. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn028 · Cited by 53

The urokinase-type plasminogen activator system in resected non-small-cell lung cancer

Salden, M., Splinter, T. A. W., Peters, H. A., Look, M. P., Timmermans, M. A. M., van Meerbeeck, J. P. A. M., & Foekens, J. A. (2000) · Annals of Oncology · doi:10.1023/a:1008312801800 · Cited by 52

A Urokinase-type Plasminogen Activator-inhibiting Cyclic Peptide with an Unusual P2 Residue and an Extended Protease Binding Surface Demonstrates New Modalities for Enzyme Inhibition

Hansen, M. A., Wind, T., Blouse, G. E., Christensen, A., Petersen, H. H., Kjelgaard, S., Mathiasen, L., Holtet, T. L., & Andreasen, P. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505933200 · Cited by 52

Inhibition of epidermal growth factor‐induced invasion by dexamethasone and AP‐1 decoy in human squamous cell carcinoma cell lines

Shiratsuchi, T., Ishibashi, H., & Shirasuna, K. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10181 · Cited by 52

Dissecting the Circuitry of Protein Kinase A and cAMP Signaling in Cancer Genesis

Cho‐Chung, Y. S., Nesterova, M., Becker, K. G., Srivastava, R. K., Park, Y. G., Lee, Y. N., Cho, Y. S., Kim, M., Neary, C. L., & Cheadle, C. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04324.x · Cited by 52

A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types

Abi‐Habib, R. J., Singh, R., Liu, S., Bugge, T. H., Leppla, S. H., & Frankel, A. E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0315 · Cited by 50

Identification of a novel inhibitor of urokinase-type plasminogen activator

Zhu, M. J., Gokhale, V. M., Szabó, L., Muñoz, R. M., Baek, H., Sridevi, B., Hurley, L. H., Hoff, D. D. V., & Han, H. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0520 · Cited by 50

In vivo Activity of the Cleaved Form of Soluble Urokinase Receptor: A New Hematopoietic Stem/Progenitor Cell Mobilizer

Selleri, C., Montuori, N., Ricci, P., Visconte, V., Baiano, A., Carriero, M. V., Rotoli, B., Rossi, G., & Ragno, P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1311 · Cited by 50

Different Roles for Plasminogen Activators and Metalloproteinases in Melanoma Metastasis

Mueller, B. M. (1996) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-61107-0_5 · Cited by 49

Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator

Frederickson, M., Callaghan, O., Chessari, G., Congreve, M., Cowan, S., Matthews, J. E., McMenamin, R. L., Smith, D.-M., Vinković, M., & Wallis, N. G. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701359z · Cited by 49

Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma

Sato, S., Kigawa, J., Minagawa, Y., Okada, M., Shimada, M., Takahashi, M., Kamazawa, S., & Terakawa, N. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991001)86:7 · Cited by 49

Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer

Maurer, G. D., Leupold, J. H., Schewe, D. M., Biller, T., Kates, R. E., Hornung, H.-M., Lau‐Werner, U., Post, S., & Allgayer, H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1668 · Cited by 49

β3A-Integrin Downregulates the Urokinase-Type Plasminogen Activator Receptor (u-PAR) through aPEA3/ets Transcriptional Silencing Element in the u-PAR Promoter

Hapke, S., Gawaz, M., Dehne, K., Köhler, J., Marshall, J. F., Graeff, H., Schmitt, M., Reuning, U., & Lengyel, E. R. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2118-2132.2001 · Cited by 49

Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.

Alonso, D. F., Tejera, Á. M., Ef, F., Joffé, E. B. D. K., & Gomez, D. E. (1998) · PubMed · Cited by 49

Blast Cell-surface and Plasma Soluble Urokinase Receptor in Acute Leukemia Patients: Relationship to Classification and Response to Therapy

Alitalo, R., Stephens, R., Vaheri, A., & Mustjoki, S. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614558 · Cited by 49

Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model

Alonso, D. F., Farias, E., Ladeda, V., Davel, L., Puricelli, L., & Joffé, E. B. D. K. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806809 · Cited by 48

Interleukin-1α enhances the aggressive behavior of pancreatic cancer cells by regulating the α6β1-integrin and urokinase plasminogen activator receptor expression

Sawai, H., Okada, Y., Funahashi, H., Matsuo, Y., Takahashi, H., Takeyama, H., & Manabe, T. (2006) · BMC Cell Biology · doi:10.1186/1471-2121-7-8 · Cited by 48

Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.

Hasui, Y., Suzumiya, J., Marutsuka, K., Sumiyoshi, A., Hashida, S., & Ishikawa, E. (1989) · PubMed · Cited by 48

Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules

Gum, R. J., Juárez, J., Allgayer, H., Mazar, A. P., Wang, Y., & Boyd, D. D. (1998) · Oncogene · doi:10.1038/sj.onc.1201917 · Cited by 48

GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system

Dondi, D., Festuccia, C., Piccolella, M., Bologna, M., & Motta, M. (2006) · Oncology Reports · doi:10.3892/or.15.2.393 · Cited by 47

Activation of Peroxisome Proliferator-Activated Receptor-γ Decreases Pancreatic Cancer Cell Invasion through Modulation of the Plasminogen Activator System

Sawai, H., Liu, J., Reber, H. A., Hines, O. J., & Eibl, G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0257 · Cited by 47

Tissue Factor Regulates Plasminogen Binding and Activation

Fan, Z., Larson, P. J., Bognacki, J. J., Raghunath, P. N., Tomaszewski, J. E., Kuo, A., Canziani, G., CHAIKEN, I. M., Cines, D. B., & Higazi, A. A. (1998) · Blood · doi:10.1182/blood.v91.6.1987 · Cited by 47

Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme

Hall, W. A., & Vallera, D. A. (2006) · Neurosurgical FOCUS · doi:10.3171/foc.2006.20.4.15 · Cited by 46

Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.

McCabe, N. P., Angwafo, F., Zaher, A., Selman, S. H., Kouinche, A., & Jankun, J. (2000) · Oncology Reports · doi:10.3892/or.7.4.879 · Cited by 46

Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer

Hasui, Y., Marutsuka, K., Asada, Y., & Osada, Y. (1996) · Urology · doi:10.1016/s0090-4295(99)80378-1 · Cited by 46

Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients

Strojan, P., Budihna, M., Šmid, L. M., Vrhovec, I., & Skrk, J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00029-x · Cited by 46

Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro

Brooks, T., Slomp, J., Quax, P. H. A., de Bart, A. C. W., Spencer, M. T., Verheijen, J. H., & Charlton, P. (2000) · Clinical & Experimental Metastasis · doi:10.1023/a:1011882421528 · Cited by 45

Systemic Delivery of Antiangiogenic Adenovirus AdmATF Induces Liver Resistance to Metastasis and Prolongs Survival of Mice

Li, H., Griscelli, F., Lindenmeyer, F., Opolon, P., Sun, L.-Q., Connault, E., Soria, J., Soria, C., Perricaudet, M., & Yeh, P. (1999) · Human Gene Therapy · doi:10.1089/10430349950016438 · Cited by 45

The Kruppel-like KLF4 Transcription Factor, a Novel Regulator of Urokinase Receptor Expression, Drives Synthesis of This Binding Site in Colonic Crypt Luminal Surface Epithelial Cells

Wang, H., Yang, L., Jamaluddin, M. S., & Boyd, D. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401257200 · Cited by 45

Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications

Pakneshan, P., Szyf, M., & Rabbani, S. A. (2005) · Current Cancer Drug Targets · doi:10.2174/156800905774574011 · Cited by 45

Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: The influence of the ester group on their biological activity

Sieńczyk, M., & Oleksyszyn, J. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.002 · Cited by 45

Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal‐regulated kinase‐dependent cascade

Kobayashi, H., Suzuki, M., Kanayama, N., Nishida, T., Takigawa, M., & Terao, T. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03068.x · Cited by 44

High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI‐2) is an independent marker for shorter progression‐free survival in patients with early stage endometrial cancer

Nordengren, J., Fredstorp-Lidebring, M., Bendahl, P., Brünner, N., Fernö, M., Högberg, T., Stephens, R. W., Wïllén, R., & Casslén, B. G. (2001) · International Journal of Cancer · doi:10.1002/ijc.1611 · Cited by 44

Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer

Steiner, E., Pollow, K., Hasenclever, D., Schormann, W., Hermes, M., Schmidt, M., Puhl, A. G., Brulport, M., Bauer, A., Petry, I. B., et al. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.025 · Cited by 44

Soluble urokinase‐type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra‐bone marrow involvement in multiple myeloma patients

Rigolin, G. M., Tieghi, A., Ciccone, M., Bragotti, L. Z., Cavazzini, F., Porta, M. G. D., Castagnari, B., Carroccia, R., Guerra, G., Cuneo, A., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04176.x · Cited by 44

Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice

Rustamzadeh, E., Hall, W. A., Todhunter, D. A., Vallera, V. D., Low, W. C., Liu, H., Panoskaltsis‐Mortari, A., & Vallera, D. A. (2006) · International Journal of Cancer · doi:10.1002/ijc.22278 · Cited by 44

A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.

Chorostowska‐Wynimko, J., Swiercz, R., Skrzypczak‐Jankun, E., Wojtowicz, A., Selman, S. H., & Jankun, J. (2003) · PubMed · Cited by 44

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours

Witte, J., Foekens, J. A., Brünner, N., Heuvel, J. J. T. M., van Tienoven, T., Look, M. P., Klijn, J. G. M., Geurts-Moespot, A. J., Grebenchtchikov, N. I., Benraad, T. J., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1867 · Cited by 43

Inhibition of metastasis of lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models

Kobayashi, H., Shinohara, H., Fujie, M., Gotoh, J., Itoh, M., Takeuchi, K., & Terao, T. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630326 · Cited by 43

High Expression of Plasminogen Activator Inhibitor‐2 (PAI‐2) is a Predictor of Improved Survival in Patients with Pancreatic Adenocarcinoma

Smith, R. C., Xue, A., Gill, A. J., Scarlett, C. J., Saxby, A. J., Clarkson, A., & Hugh, T. J. (2007) · World Journal of Surgery · doi:10.1007/s00268-006-0289-9 · Cited by 43

Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor–independent urokinase-type plasminogen activator inhibition

Oh, S., Lee, O.-H., Schroeder, C. P., Oh, Y. W., Shi, K., Cha, H., Park, R., Onn, A., Herbst, R. S., Li, C., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0142 · Cited by 43

Small interfering RNA induced transcriptional gene silencing in human cells

Morris, K. V. (2007) · ˜The œbiomedical & life sciences collection. · doi:10.69645/vhcz2546 · Cited by 43

Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin.

Behrendt, N., Rønne, E., & Danø, K. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53416-5 · Cited by 42

Inhibition of tumor cell invasion through matrigel by a peptide derived from the domain II region in urinary trypsin inhibition.

Kobayashi, H., Gotoh, J., Kanayama, N., Hirashima, Y., Terao, T., & Sugino, D. (1995) · PubMed · Cited by 42

Synthesis, Solution Structure, and Biological Evaluation of Urokinase Type Plasminogen Activator (uPA)-Derived Receptor Binding Domain Mimetics

Schmiedeberg, N., Schmitt, M., Rölz, C., Truffault, V., Sukopp, M., Bürgle, M., Wilhelm, O. G., Schmalix, W. A., Magdolen, V., & Kessler, H. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020254q · Cited by 42

Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses

Yang, H., Henkin, J., Kim, K. H., & Greer, J. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00173a008 · Cited by 42

On receptor inhibitors and chemotherapy.

Ryan, P. D., & Chabner, B. A. (2000) · PubMed · Cited by 42

Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas

Ulisse, S., Baldini, E., Toller, M., Marchioni, E., Giacomelli, L., Antoni, E. D., Ferretti, E., Marzullo, A., Graziano, F. M., Trimboli, P., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.04.017 · Cited by 41

Inherent Instability of Plasminogen Activator Inhibitor Type 2 mRNA Is Regulated by Tristetraprolin

Yu, H., Stasinopoulos, S. J., Leedman, P. J., & Medcalf, R. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213027200 · Cited by 41

Activation of CD95L fusion protein prodrugs by tumor-associated proteases

Watermann, I., Gerspach, J., Lehne, M., Seufert, J., Schneider, B., Pfizenmaier, K., & Wajant, H. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402051 · Cited by 40

Role of C‐Jun and Proximal Phorbol 12‐Myristate‐13‐Acetate‐(PMA)‐Responsive Elements in the Regulation of Basal and PMA‐Stimulated Plasminogen‐Activator Inhibitor‐1 Gene Expression in HepG2

Arts, J., Grimbergen, J. M., Bosma, P. J., Rahmsdorf, H. J., & Kooistra, T. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.00393.x · Cited by 40

Enhanced Stability of Urokinase‐Type Plasminogen Activator mRNA in Metastatic Breast Cancer MDA‐MB‐231 Cells and LLC‐PK1 Cells Down‐Regulated for Protein Kinase C — Correlation with Cytoplasmic Heterogeneous Nuclear Ribonucleoprotein C

Nanbu, R., Montero, L., D'Orazio, D., & Nagamine, Y. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00169.x · Cited by 40

RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth

Kondraganti, S., Gondi, C. S., McCutcheon, I. E., Dinh, D., Gujrati, M., Rao, J., & Olivero, W. C. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.6.1353 · Cited by 40

A Novel Type of Bifunctional Inhibitor Directed against Proteolytic Activity and Receptor/Ligand Interaction

Muehlenweg, B., Assfalg‐Machleidt, I., Gil-Parrado, S., Bürgle, M., Creutzburg, S., Schmitt, M., Auerswald, E. A., Machleidt, W., & Magdolen, V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000383200 · Cited by 39

A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells

Croucher, D. R., Saunders, D. N., Stillfried, G. E., & Ranson, M. (2007) · Biochemical Journal · doi:10.1042/bj20070767 · Cited by 39

Cellular Distribution and Clinical Value of Urokinase-Type Plasminogen Activator, Its Receptor, and Plasminogen Activator Inhibitor-2 in Esophageal Squamous Cell Carcinoma

Shiomi, H., Eguchi, Y., Tani, T., Kodama, M., & Hattori, T. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64761-x · Cited by 39

Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer

Zhang, L. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i25.3970 · Cited by 38

Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis

Loktionov, A. S. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00556-6 · Cited by 38

Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis

Champelovier, P., Boucard, N., Levacher, G., Simon, A., Seigneurin, D., & Praloran, V. (2002) · Urological Research · doi:10.1007/s00240-002-0270-5 · Cited by 38

Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator

Mohanam, S., Chandrasekar, N., Yanamandra, N., Siddique, K., Mirza, F., Dinh, D. H., Olivero, W. C., & Rao, J. S. (2002) · Oncogene · doi:10.1038/sj.onc.1205893 · Cited by 38

Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.

Luther, T., Kotzsch, M., Meye, A., Langerholc, T., Füssel, S., Olbricht, N., Albrecht, S., Ockert, D., Muehlenweg, B., Friedrich, K., et al. (2003) · PubMed · doi:10.1267/thro03040705 · Cited by 38

Analysis of the invasion-metastasis mechanism in pancreatic cancer: Involvement of plasmin(ogen) cascade proteins in the invasion of pancreatic cancer cells

Tan, X., Egami, H., Nozawa, F., Abe, M., & Baba, H. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.2.369 · Cited by 37

Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells

Simeone, A., Nieves-Alicea, R., McMurtry, V., Colella, S., Krahe, R., & Tari, A. M. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.4.785 · Cited by 37

Tumor-Associated Proteolytic Factors uPA and PAI-1: Critical Appraisal of Their Clinical Relevance in Breast Cancer and Their Integration into Decision-Support Algorithms

Harbeck, N., Schmitt, M., Paepke, S., Allgayer, H., & Kates, R. E. (2007) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360601040970 · Cited by 37

Regulation of Urokinase Receptor Expression by p53: Novel Role in Stabilization of uPAR mRNA

Shetty, S., Velusamy, T., Idell, S., Shetty, P. K., Mazar, A. P., Bhandary, Y. P., & Shetty, R. R. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00080-07 · Cited by 37

Antitumor efficacy of a urokinase activation–dependent anthrax toxin

Rønø, B., Rømer, J., Liu, S., Bugge, T. H., Leppla, S. H., & Kristjansen, P. E. G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0163 · Cited by 37

Therapeutic efficacy of once‐daily oral administration of a Kunitz‐type protease inhibitor, bikunin, in a mouse model and in human cancer

Kobayashi, H., Yagyu, T., Inagaki, K., Kondo, T., Suzuki, M., Kanayama, N., & Terao, T. (2004) · Cancer · doi:10.1002/cncr.20034 · Cited by 36

Suramin in adrenocortical cancer: limited efficacy and serious toxicity

Arlt, W., Reincke, M., Siekmann, L., WInkelmann, W., & Allolio, B. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02549.x · Cited by 36

High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis

Graf, M., Reif, S., Hecht, K., Pelka‐Fleischer, R., Pfister, K., & Schmetzer, H. M. (2005) · American Journal of Hematology · doi:10.1002/ajh.20337 · Cited by 36

Plasminogen Activator Inhibitor Type 2 Gene Induction by Tumor Necrosis Factor and Phorbol Ester Involves Transcriptional and Post-transcriptional Events

Maurer, F., & Medcalf, R. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.42.26074 · Cited by 36

Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-Isoquinolinylguanidines

Barber, C., DICKINSON, R. P., & Fish, P. V. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.03.094 · Cited by 36

Alpha 2-plasmin inhibitor and its deficiency states.

Saito, H. (1988) · PubMed · Cited by 36

Targeting the Over-Expressed Urokinase-Type Plasminogen Activator Receptor on Glioblastoma Multiforme

Rustamzadeh, E., Li, C., Doumbia, S., Hall, W. A., & Vallera, D. A. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1026238331739 · Cited by 35

Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions

Daneri‐Navarro, A., Macías-López, G. G., Oceguera‐Villanueva, A., del Toro‐Arreola, S., Bravo‐Cuéllar, A., Pérez‐Montfort, R., & Orbach-Arbouys, S. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10038-7 · Cited by 35

The inhibitory effects of immunosuppressive factors, dexamethasone and interleukin-4, on NF-κB-mediated protease production by oral cancer

Beppu, M., Ikebe, T., & Shirasuna, K. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(01)00080-1 · Cited by 35

Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects ofHelicobacter pylori

Iwamoto, J., Mizokami, Y., Takahashi, K., Nakajima, K., Ohtsubo, T., Miura, S., Narasaka, T., Takeyama, H., Omata, T., Shimokobe, K., et al. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510015665 · Cited by 35

Expression of UPA and UPAR is associated with the clinical course of urinary bladder neoplasms

Seddighzadeh, M., Steineck, G., Larsson, P., Wijkström, H., Norming, U., Onelöv, E., & Linder, S. T. (2002) · International Journal of Cancer · doi:10.1002/ijc.10426 · Cited by 35

PEGylated DX-1000: Pharmacokinetics and Antineoplastic Activity of a Specific Plasmin Inhibitor

Devy, L., Rabbani, S. A., Stochl, M., Ruskowski, M., Mackie, I. J., Naa, L., Toews, M., van Gool, R., Chen, J., Ley, A., et al. (2007) · Neoplasia · doi:10.1593/neo.07544 · Cited by 35

Plasminogen activator inhibitor‐1 as a potential marker for the malignancy of gastric cancer

Sakakibara, T., Hibi, K., Koike, M., Fujiwara, M., Kodera, Y., Ito, K., & Nakao, A. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00185.x · Cited by 35

Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array

Hofmann, H., Bartling, B., Simm, A., Murray, R., Aziz, N. A., Hansen, G., Silber, R., & Burdach, S. E. G. (2006) · Oncology Reports · doi:10.3892/or.16.3.587 · Cited by 35

Expression of E-Cadherin and uPA and their Association with the Prognosis of Pancreatic Cancer

Shin, S. J., Kim, K. O., Kim, M. K., Lee, K. H., Hyun, M. S., Kim, K., Choi, J. H., & SONG, H. S. (2005) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyi094 · Cited by 35

The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas

Giannopoulou, I., Mylona, E., Kapranou, A., Mavrommatis, J., Markaki, S., Zoumbouli, C., Keramopoulos, A., & Nakopoulou, L. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.03.003 · Cited by 35

Regulation of the plasminogen activator inhibitor type-2 gene in monocytes: localization of an upstream transcriptional silencer

Antalis, T., Costelloe, E. O., Muddiman, J. D., Ogbourne, S. M., & Donnan, K. (1996) · Blood · doi:10.1182/blood.v88.10.3686.bloodjournal88103686 · Cited by 35

Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer

Tecimer, C., Doering, D. L., Goldsmith, L. J., Meyer, J. S., Abdulhay, G., & Wittliff, J. L. (2000) · International Journal of Gynecological Cancer · doi:10.1046/j.1525-1438.2000.010005372.x · Cited by 34

Suramin in Non-small Cell Lung Cancer and Advanced Breast Cancer: Two Parallel Phase II Studies

Mirza, M. R., Jakobsen, E. H., Pfeiffer, P., Lindebjerg-Clasen, B., Bergh, J. C. S., & Rose, C. (1997) · Acta Oncologica · doi:10.3109/02841869709109226 · Cited by 34

Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.

Swiercz, R., Wolfe, J. D., Zaher, A., & Jankun, J. (1998) · PubMed · Cited by 34

Motifs Resembling Hepatocyte Nuclear Factor 1 and Activator Protein 3 Mediate the Tissue Specificity of the Human Plasminogen Gene

Meroni, G., Buraggi, G., Mantovani, R., & Taramelli, R. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.00373.x · Cited by 33

Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors

Rao, J. S., Rayford, A., Morantz, R. A., Festoff, B. W., & Sawaya, R. A. (1993) · Journal of Neuro-Oncology · doi:10.1007/bf01049977 · Cited by 33

Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma

Naka, T., Kuester, D., Boltze, C., Schulz, T., Samii, A., Herold, C., Ostertag, H., & Roessner, A. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.06.005 · Cited by 33

Crystals of Urokinase Type Plasminogen Activator Complexes Reveal the Binding Mode of Peptidomimetic Inhibitors

Żesławska, E., Jacob, U., Schweinitz, A., Coombs, G. S., Bode, W., & Madison, E. L. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00267-5 · Cited by 33

CpG methylation of the PAI-1 gene 5’-flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines

Skeldal, S., Krogdahl, A., Sørensen, J. A., Andreasen, P. A., & Gao, S. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-02-0114 · Cited by 33

Significant overexpression of urokinase‐type plasminogen activator in pancreatic adenocarcinoma using real‐time quantitative reverse transcription polymerase chain reaction

Nielsen, A., Scarlett, C. J., Samra, J. S., Gill, A. J., Li, Y., Allen, B., & Smith, R. C. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03531.x · Cited by 33

The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: Relation to prognosis

Pappot, H., Pedersen, A. N., Brünner, N., & Christensen, I. J. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.10.002 · Cited by 33

Inhibition of Sp1 activity by a decoy PNA–DNA chimera prevents urokinase receptor expression and migration of breast cancer cells

Zannetti, A., Vecchio, S. D., Romanelli, A., Scala, S., Saviano, M., Calı̀, G., Stoppelli, M. P., Pedone, C., & Salvatore, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.07.024 · Cited by 32

Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue

Almasi, C. E., Høyer‐Hansen, G., Christensen, I. J., Danø, K., & Pappot, H. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.11.020 · Cited by 32

Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines

Barber, C., DICKINSON, R. P., & Horne, V. A. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00701-6 · Cited by 32

Cyclo19,31[D-Cys19]-uPA19-31 Is a Potent Competitive Antagonist of the Interaction of Urokinase-Type Plasminogen Activator with Its Receptor (CD87)

Magdolen, V., Bürgle, M., de Prada, N. A., Schmiedeberg, N., Riemer, C., Schroeck, F. R., Kellermann, J., Degitz, K., Wilhelm, O. G., Schmitt, M., et al. (2001) · Biological Chemistry · doi:10.1515/bc.2001.150 · Cited by 32

Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor

Nozaki, S., Endo, Y., Nakahara, H., Yoshizawa, K., Hashiba, Y., Kawashiri, S., Tanaka, A., Nakagawa, K., Matsuoka, Y., Kogo, M., et al. (2005) · Oral Oncology · doi:10.1016/j.oraloncology.2005.05.013 · Cited by 32

Structure of Human α2-Plasmin Inhibitor Deduced from the cDNA Sequence1

Tone, M., Kikuno, R. F., Kume-Iwaki, A., & Hashimoto-Gotoh, T. (1987) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a122141 · Cited by 31

High Level Synthesis of Recombinant Soluble Urokinase Receptor (CD87) by Ovarian Cancer Cells Reduces Intraperitoneal Tumor Growth and Spread in Nude Mice

Lutz, V., Reuning, U., Krüger, A., Luther, T., von Steinburg, S. P., Graeff, H., Schmitt, M., Wilhelm, O. G., & Magdolen, V. (2001) · Biological Chemistry · doi:10.1515/bc.2001.095 · Cited by 31

Urokinase Plasminogen Activator Receptor and Soluble Matrix Metalloproteinase-9 in Acute Myeloid Leukemia Patients: A Possible Relation to Disease Invasion

Aref, S., El-Sherbiny, M., Mabed, M., Menessy, A., & El‐Refaei, M. F. (2003) · Hematology · doi:10.1080/10245330310001621323 · Cited by 31

Helicobacter pylori stimulates urokinase plasminogen activator receptor expression and cell invasiveness through reactive oxygen species and NF-κB signaling in human gastric carcinoma cells

Kim, M. H., Yoo, H., Jang, H., Baek, M. J., Kim, H., Kim, K. K., Shin, B. A., Ahn, B. W., & Jung, Y. D. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.19.4.689 · Cited by 31

Preoperative Plasma Soluble Urokinase Plasminogen Activator Receptor as a Prognostic Marker in Rectal Cancer Patients. An Eortc-Receptor and Biomarker Group Collaboration

Riisbro, R., Christensen, I. J., Nielsen, H. J., Brünner, N., Nilbert, M. C., & Fernebro, E. (2005) · The International Journal of Biological Markers · doi:10.1177/172460080502000203 · Cited by 31

Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer.

Koutsilieris, M., Reyes‐Moreno, C., Sourla, A., Dimitriadou, V., & Choki, I. (1997) · PubMed · Cited by 30

Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13

Rustamzadeh, E., Vallera, D. A., Todhunter, D. A., Low, W. C., Panoskaltsis‐Mortari, A., & Hall, W. A. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9051-7 · Cited by 30

Prognostic value of plasminogen activator inhibitor‐1 in head and neck squamous cell carcinoma

Speleman, L., Kerrebijn, J. D. F., Look, M. P., Meeuwis, C. A., Foekens, J. A., & Berns, E. M. J. J. (2006) · Head & Neck · doi:10.1002/hed.20527 · Cited by 30

Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells

Thomas, S., Muralidharan, A., & Shah, G. V. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.6.1425 · Cited by 29

Inhibition of urokinase receptor gene expression and cell invasion by anti‐uPAR DNAzymes in osteosarcoma cells

de Bock, C. E., Lin, Z., Itoh, T., Morris, D. L., Murrell, G. A. C., & Wang, Y. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.04778.x · Cited by 29

Plasminogen Activator Inhibitor-1 as a Potential Marker for the Malignancy of Esophageal Squamous Cell Carcinoma

Sakakibara, T., Hibi, K., Kodera, Y., Ito, K., Akiyama, S., & Nakao, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0196 · Cited by 29

EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor

Hénic, E., Sixt, M., Hansson, S. R., Høyer‐Hansen, G., & Casslén, B. G. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.038 · Cited by 29

Pretreatment Determination of the Serum Urokinase Plasminogen Activator and its Soluble Receptor in Advanced Small-Cell Lung Cancer or Non-Small-Cell Lung Cancer

Cobos, E., Jumper, C., & Lox, C. D. (2003) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602960300900309 · Cited by 29

Diabetes and Cancer

Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366

Diabetes and Cancer: A Consensus Report

Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,082

Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry

Mucha, A., Kafarski, P. K., & Berlicki, Ł. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200587f · Cited by 679

Exploring the next generation of antibody–drug conjugates

Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659

The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets

Wood, S. L., Pernemalm, M., Crosbie, P. A. J., & Whetton, A. D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.001 · Cited by 494

The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies

Su, S.-C., Lin, C.-W., Yang, W.-E., Fan, W.-L., & Yang, S.-F. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1113260 · Cited by 145

Evolving role of uPA/uPAR system in human cancers

Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., & Sarkar, F. H. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.10.005 · Cited by 421

Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.

Choong, P., & Nadesapillai, A. P. W. (2003) · PubMed · doi:10.1097/01.blo.0000093845.72468.bd · Cited by 168

Urokinase Plasminogen Activator

Salajegheh, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-28140-7_57 · Cited by 3

The urokinase plasminogen activator system as a novel target for tumour therapy

Schmitt, M., Wilhelm, O. G., Reuning, U., Krüger, A., Harbeck, N., Lengyel, E. R., Graeff, H., Gänsbacher, B., Kessler, H., Bürgle, M., et al. (2000) · Fibrinolysis and Proteolysis · doi:10.1054/fipr.2000.0079 · Cited by 107